Project Grant R21CA281729

Award Date 6/14/24
Completion Date 5/31/26
Dollars Obligated $372K
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Columbia, SC 29208, USA
Similar Awards
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), will provide $192,610 to The University of Kentucky Research Foundation over a 2-year period from April 1, 2025 to March 31, 2027. The primary objective of this study is to evaluate the impact of various social determinants of health (SDOH) on early-onset colorectal cancer (EOCRC) diagnosis, treatment delays, and survival, with a focus on geographically...
The National Cancer Institute (NCI), through its Cancer Research Manpower (CFDA 93.398) Federal Grant Program, awarded a $108,706 Project Grant to The Trustees of the University of Pennsylvania (UPenn) to investigate the role of diet and the enzyme ACSS2 in regulating metabolism and epigenetics in colorectal cancer (CRC). The 2-year project aims to determine how the dietary compounds fructose and acetate (from fiber) interact to influence CRC growth and acetyl-CoA metabolism, as well as identify...
The National Cancer Institute (NCI) awarded a $224,099 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of California, San Diego (UCSD) to develop a targeted colorectal cancer (CRC) screening strategy for adults aged 45-49. The key objectives are to: Characterize the acceptability of CRC screening among this age group through a pilot trial and surveys/interviews to identify effective screening implementation strategies. Conduct a randomized controlled...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a first-of-its-kind intervention against colorectal cancer (CRC) associated with colibactin-producing bacteria. The $627,422 award to the Regents of the University of Michigan will fund research to engineer commensal E. coli bacteria to display an enzyme that neutralizes the carcinogenic colibactin toxin. The project has three key objectives: 1) further optimize the...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $551,848 to the Dana-Farber Cancer Institute, Inc. (DFCI) to investigate the molecular mechanisms of developmental reprogramming in colorectal cancer (CRC). The key objectives are to identify regulators of fetal gene reactivation in CRC cells, determine if the transcription factor SOX9 directly controls fetal gene expression, and evaluate the...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $415,257 to the University of Virginia to conduct research aimed at identifying epigenetic and transcriptomic drivers of racial disparities in colorectal cancer risk and site-specific tumor development. The key products and services to be delivered under this 2-year award include: Identifying site-specific DNA methylation-associated gene expression signatures across different...
This federal Project Grant award from the National Institute on Minority Health and Health Disparities (NIMHD), under the Minority Health and Health Disparities Research (CFDA 93.307) program, provides $1,287,400.00 to The University of Texas Southwestern Medical Center (UT Southwestern) to study early-onset colorectal cancer (EOCRC) among an underserved patient population in Dallas, Texas. The primary objectives are to: 1) Describe the symptom burden and healthcare system interactions leading...
This National Cancer Institute (CFDA 93.396 Cancer Biology Research) Project Grant award to the Icahn School of Medicine at Mount Sinai in the amount of $560,297 will fund a 5-year research project to functionally characterize "oncofetal stem cells" in colorectal cancer (CRC). The project aims to: Generate reporters to track the dynamics of CRC stem cell populations, including oncofetal stem cells and LGR5+ cancer stem cells. The researchers will then use these reporters coupled to a...
The National Cancer Institute awarded a $406,611 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of Texas Health Science Center at Houston (UTHealth) to investigate the role and therapeutic targeting of the GPR56 protein in colorectal cancer. The key objectives of this 5-year research project are to: 1) characterize the role and signaling mechanisms of GPR56 in colorectal cancer stem cells and metastasis using patient-derived organoids, 2) develop and evaluate highly...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research investigating the role of the bacterial species Fusobacterium nucleatum (Fn) and the protein Annexin A1 in the development and progression of colorectal cancer. The award totaling $600,499 will fund research to: (I) examine the mechanisms by which the amyloid-like form of the Fn adhesin protein FadA stimulates colorectal cancer growth, and (II) investigate the function of Annexin...

THE ROLE OF EARLY LIFE EXPOSURE TO ANTIBIOTICS ON RISK OF EARLY ONSET COLORECTAL CANCER - PROJECT SUMMARY/ABSTRACT THE INCIDENCE OF EARLY ONSET COLORECTAL CANCER (EOCRC) HAS INCREASED IN THE PAST FOUR DECADES AND IS PREDICTED TO INCREASE BY 140% BY 2030.4,5 IT IS THE SECOND MOST COMMON CANCER AND THIRD LEADING CAUSE OF CANCER DEATHS IN INDIVIDUALS UNDER 50 YEARS OLD IN THE USA.4,6,7 IN A RECENT REVIEW47, WE PROPOSED THAT INCREASED RISK OF EOCRC IS DRIVEN BY EXPOSOMES WHOSE ENTRY INTO THE GLOBAL ENVIRONMENT PRECEDES AND MIMICS THE WORLDWIDE INCREASE IN EOCRC INCIDENCE. EXPOSURE TO THESE SUSPECTED EXPOSOMES HAS BEEN INCREASING IN THE PAST 40 YEARS (AS HAS EOCRC), AND THEY ALL IMPACT GUARDIANS OF THE COLON (INFLAMMATION, THE MICROBIOME, AND EPIGENETIC/GENETIC CHANGES); EXPOSURE IS GLOBAL AND OCCURS DURING DEVELOPMENT - POTENTIALLY DURING CHILDHOOD. IN THIS PROJECT, WE FOCUS ON THE ROLE OF EXPOSURE TO ANTIBIOTICS DURING DEVELOPMENT AND ITS ON IMPACT EOCRC IN APPROPRIATE PRE-CLINICAL MODELS. ANTIBIOTIC OVERUSE HAS BECOME A SERIOUS PUBLIC HEALTH CONCERN, WITH OVER A MILLION DOSES PRESCRIBED ANNUALLY IN THE US.50,23 ITS USE IN INFANTS IS HIGH; OVER 50% ARE DIRECTLY EXPOSED FOR >5 DAYS.17 INDIRECT EXPOSURE IN PREGNANCY AFFECTS INFANT GUT MICROBIOTA AT BIRTH19,20; AND AT AN EARLY AGE, EXPOSURE CAN LEAD TO MULTIPLE HEALTH DISORDERS - INCLUDING CRC.21,22,23 REPEATED EXPOSURES CONTRIBUTE TO ANTIBIOTIC RESISTANCE AND ALTERED GUT MICROBIOTA WITH PRO-INFLAMMATORY AND PRO-CARCINOGENIC OUTCOMES28-32, SUGGESTING THAT THERE MAY BE WINDOWS OF DEVELOPMENTAL VULNERABILITY. HOWEVER, EPIDEMIOLOGIC AND ANIMAL STUDIES HAVE SHOWN CONFLICTING RESULTS, WITH NONE CONDUCTED ON THE IMPACT OF ANTIBIOTICS COMMONLY PRESCRIBED TO INFANTS AND CHILDREN ON THE COLON, CREATING A SUBSTANTIAL GAP IN OUR KNOWLEDGE ON THE MECHANISMS BY WHICH ANTIBIOTICS IMPACT EOCRC. WE WILL ADDRESS THIS GAP BY TESTING THE HYPOTHESIS THAT EXPOSURE EARLY IN LIFE TO ANTIBIOTICS COMMONLY PRESCRIBED TO CHILDREN CAUSES A TOXIC COLON (ASSOCIATED WITH DYSBIOSIS, INFLAMMATION, AND ALTERED GENETIC SIGNATURES) THAT PROMOTE MUTATIONS LEADING TO EOCRC. USING MOUSE MODELS OF CRC, WE WILL TEST THIS HYPOTHESIS IN TWO SPECIFIC AIMS: AIM 1. TO IDENTIFY DEVELOPMENTAL WINDOWS OF SUSCEPTIBILITY TO ANTIBIOTICS; AIM 2. TO DETERMINE IF DYSBIOSIS CAUSED BY ANTIBIOTICS DRIVES EOCRC. UPON COMPLETION, WE WILL KNOW: (1) THE IMPACT OF ANTIBIOTICS ON EOCRC RISK; (2) DEVELOPMENTAL WINDOWS OF COLON SUSCEPTIBILITY TO ANTIBIOTICS; (3) WHAT MICROBES DRIVE EOCRC; AND (4) WHETHER THESE MICROORGANISMS PROMOTE INCREASED MUTATION AS A MECHANISM CAUSING CRC. THE ACQUIRED KNOWLEDGE WILL BE CRITICAL IN DEVELOPING NOVEL STRATEGIES TO IDENTIFY INDIVIDUALS AT RISK, INTERVENTIONS TO MINIMIZE RISK OF EOCRC, AND INFORMED DECISIONS TO MITIGATE RISK AFTER USE OF ANTIBIOTICS THAT ARE INDISPENSABLE AGAINST INFECTIONS, AND MORE IMPORTANTLY, PROVIDE THE FOUNDATION FOR FUTURE STUDIES TO IDENTIFY COMPONENTS OF HUMAN MICROBIOME THAT MEDIATE INCREASED RISK FOR EOCRC.

Posted 6/20/24, 12:00 AM